Compare VIR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | CDNA |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.0B |
| IPO Year | 2019 | 2007 |
| Metric | VIR | CDNA |
|---|---|---|
| Price | $10.89 | $20.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $19.63 | ★ $27.60 |
| AVG Volume (30 Days) | ★ 1.8M | 705.6K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,556,000.00 | $48,324,000.00 |
| Revenue This Year | $270.22 | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $4.16 | $10.96 |
| 52 Week High | $11.66 | $23.24 |
| Indicator | VIR | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 62.21 |
| Support Level | $5.18 | $16.63 |
| Resistance Level | $10.91 | $21.05 |
| Average True Range (ATR) | 0.53 | 1.25 |
| MACD | 0.16 | 0.52 |
| Stochastic Oscillator | 73.75 | 69.01 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.